In the following video, Motley Fool healthcare analyst David Williamson takes a look at Eli Lilly's (LLY +0.25%) CEO, John Lechleiter, examining both how his background as a scientist makes him an a rarity in big pharma and highlighting his rise to the top of Eli Lilly. David then tells investors why Lechleiter's background is both a strength for the company -- and a potential weakness.
